Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

Status:

Topic selection

Technology type:

Medicine

Decision:

Not selected

Further information:

Decision makers have concluded that the clear rationale to not evaluate your product is due to a clinical guideline (CG150) being available that already which includes a recommendation for the use of combination therapy with an oral triptan and an NSAID for the acute treatment of migraine. Therefore, a TA would not add any further value.

ID number:

12055

Project Team

Project lead

Danielle Lees

Email enquiries

If you have any queries please email [email protected]

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about prioritising our guidance topics